Clinical Trials Browser

Phase 3 × Neoplasm, Residual × Irinotecan × Clear all

NCT05427669 2022-10-07

AFFORD

Phase 3 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual